

ASX Announcement | 13 January 2026

AdAlta Limited (ASX:1AD)

Investor Webinar: “East to West” strategy and BZDS1901 transaction update

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products will host a virtual investor webinar on 15 January 2026..

AdAlta’s CEO and Managing Director, Dr Tim Oldham will discuss:

- The recently announced (2 January 2026) collaboration between AdAlta’s subsidiary company, AdCella, and Shanghai Cell Therapy Group to develop BZDS1901, a ground breaking armoured CAR-T cell therapy for mesothelioma and other solid cancers, for global markets.
- Next steps for advancing the “East to West” cellular immunotherapy strategy and AdCella financing.

The presentation will be followed by an opportunity for investor questions.

Webinar details are:

Thursday, 15 January 2026

1:00 – 1:40 pm AEST

Register (free) here: <https://investorhub.adalta.com.au/webinars/mepmBr-breakthrough-car-t-licensing-transaction>

This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham

CEO & Managing Director

P: +61 3 9479 5159

E: t.oldham@adalta.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model

delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)